United Therapeutics Corporation
UTHR
주식 순위
#1000
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
주가
$551.89
마지막 동기화: 2026-10-20
시가총액
$23.67B
변동 (1일)
1.61%
변동 (1년)
30.61%
국가
US
거래 United Therapeutics Corporation (UTHR)
카테고리
Healthcare
United Therapeutics Corporation (UTHR)의 매출
Jun 2026 기준 매출 TTM: $3.15B
United Therapeutics Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $3.15B입니다. 2023년에 회사는 $2.33B의 수익을 올렸으며 이는 2022년의 $1.94B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
United Therapeutics Corporation의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $3.15B | 9.63% |
| 2024 | $2.88B | 23.63% |
| 2023 | $2.33B | 20.20% |
| 2022 | $1.94B | 14.88% |
| 2021 | $1.69B | 13.63% |
| 2020 | $1.48B | 2.38% |
| 2019 | $1.45B | -11.00% |
| 2018 | $1.63B | -5.65% |
| 2017 | $1.73B | 7.91% |
| 2016 | $1.60B | 9.08% |
| 2015 | $1.47B | 13.76% |
| 2014 | $1.29B | 15.36% |
| 2013 | $1.12B | 21.93% |
| 2012 | $916.08M | 23.26% |
| 2011 | $743.18M | 23.08% |
| 2010 | $603.83M | 63.26% |
| 2009 | $369.85M | 31.39% |
| 2008 | $281.50M | 33.45% |
| 2007 | $210.94M | 32.14% |
| 2006 | $159.63M | 37.71% |
| 2005 | $115.92M | 57.51% |
| 2004 | $73.59M | 37.96% |
| 2003 | $53.34M | 77.09% |
| 2002 | $30.12M | 425.50% |
| 2001 | $5.73M | 179.70% |
| 2000 | $2.05M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 300.20% |
US
|
|
| $2.23B | -29.37% |
US
|
|
| $15.74B | 399.11% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 90.88% |
NL
|
